← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Oligomerix, Inc
New York, NY
$26,679,439
Total funding
10
Grants
Funding over time
peak $5.2M · FY2007–25$10M$7.5M$5M$2.5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,679,439 · 10
By mechanism
R44$21,253,368 · 6
R01$4,567,070 · 1
R43$859,001 · 3
Investigators at Oligomerix, Inc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
First in Human Study of a Tau Self-Association Small Molecule Inhibitor in Healthy Volunteers$2,039,616
R01 · FY2023 · AG
First in Human Study of a Tau Self-Association Small Molecule Inhibitor in Healthy Volunteers$1,917,889
R01 · FY2022 · AG
GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development forADRD$1,497,873
R44 · FY2024 · AG
GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development forADRD$1,496,276
R44 · FY2023 · AG
Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD$1,452,237
R44 · FY2020 · AG
A 26-week rat toxicity study and efficacy and biomarker studies in Tau-APP Alzheimer's mouse model to support a Phase 1b clinical study$1,367,955
R44 · FY2023 · AG
Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD$1,290,570
R44 · FY2021 · AG
GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development for ADRD$1,228,934
R44 · FY2019 · AG
A 26-week rat toxicity study and efficacy and biomarker studies in Tau-APP Alzheimer's mouse model to support a Phase 1b clinical study$1,124,972
R44 · FY2022 · AG
Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD$999,982
R44 · FY2019 · AG
Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD$999,937
R44 · FY2020 · AG
Tau oligomer platform validation using lead series candidate in htau mice$999,248
R44 · FY2018 · AG
Tau oligomer platform validation using lead series candidate in htau mice$983,729
R44 · FY2019 · AG
GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development for ADRD$954,537
R44 · FY2020 · AG
High throughput tau oligomer assay for drug screening for Alzheimer's disease$917,397
R44 · FY2010 · AG
High throughput tau oligomer drug screening assay for Alzheimer's disease$903,675
R44 · FY2013 · AG
High throughput tau oligomer drug screening assay for Alzheimer's disease$814,009
R44 · FY2014 · AG
Tau Oligomer Platform Validation Using Lead Series Candidate in htau Mice$749,795
R44 · FY2017 · AG
Tau Oligomer Platform Validation Using Lead Series Candidate in htau Mice$749,795
R44 · FY2016 · AG
High throughput tau oligomer assay for drug screening for Alzheimer's disease$732,203
R44 · FY2011 · AG